Literature DB >> 23468071

Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders.

Brian Reichow1, Fred R Volkmar, Michael H Bloch.   

Abstract

Many children with pervasive developmental disorders (PDD) exhibit behaviors and symptoms of attention-deficit/hyperactivity disorder (ADHD). We sought to determine the relative efficacy of medications for treating ADHD symptoms in children with PDD by identifying all double-blind, randomized, placebo-controlled trials examining the efficacy of medications for treating ADHD symptoms in children with PDD. We located seven trials involving 225 children. A random effects meta-analysis of four methylphenidate trials showed methylphenidate to be effective for treating ADHD symptoms in children with PDD (ES = .67). Several adverse events were greater for children were taking methylphenidate compared to placebo. An individual trial of clonidine and two trials of atomoxetine suggest these agents may also be effective in treating ADHD symptoms in children with PDD.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23468071      PMCID： PMC3787525          DOI： 10.1007/s10803-013-1793-z

Source DB:  PubMed          Journal:  J Autism Dev Disord        ISSN： 0162-3257


  31 in total

1.  A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1999-12

2.  Acute and long-term safety and tolerability of risperidone in children with autism.

Authors:  Michael G Aman; L Eugene Arnold; Christopher J McDougle; Benedetto Vitiello; Lawrence Scahill; Mark Davies; James T McCracken; Elaine Tierney; Patricia L Nash; David J Posey; Shirley Chuang; Andres Martin; Bhavik Shah; Nilda M Gonzalez; Naomi B Swiezy; Louise Ritz; Kathleen Koenig; James McGough; Jaswinder K Ghuman; Ronald L Lindsay
Journal:  J Child Adolesc Psychopharmacol       Date:  2005-12       Impact factor: 2.576

3.  Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  2005-11

4.  Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.

Authors:  B L Handen; C R Johnson; M Lubetsky
Journal:  J Autism Dev Disord       Date:  2000-06

Review 5.  Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle.

Authors:  T Spencer; J Biederman; T Wilens; M Harding; D O'Donnell; S Griffin
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1996-04       Impact factor: 8.829

6.  How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis.

Authors:  H M Schachter; B Pham; J King; S Langford; D Moher
Journal:  CMAJ       Date:  2001-11-27       Impact factor: 8.262

7.  Use of methylphenidate in the treatment of children with autistic disorder.

Authors:  H Quintana; B Birmaher; D Stedge; S Lennon; J Freed; J Bridge; L Greenhill
Journal:  J Autism Dev Disord       Date:  1995-06

8.  A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders.

Authors:  Kimberly A Stigler; Lael A Desmond; David J Posey; Ryan E Wiegand; Christopher J McDougle
Journal:  J Child Adolesc Psychopharmacol       Date:  2004       Impact factor: 2.576

9.  Clonidine treatment of hyperactive and impulsive children with autistic disorder.

Authors:  C A Jaselskis; E H Cook; K E Fletcher; B L Leventhal
Journal:  J Clin Psychopharmacol       Date:  1992-10       Impact factor: 3.153

10.  Are autism spectrum disorder and attention-deficit/hyperactivity disorder different manifestations of one overarching disorder? Cognitive and symptom evidence from a clinical and population-based sample.

Authors:  Jolanda M J van der Meer; Anoek M Oerlemans; Daphne J van Steijn; Martijn G A Lappenschaar; Leo M J de Sonneville; Jan K Buitelaar; Nanda N J Rommelse
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2012-09-30       Impact factor: 8.829
View more
  26 in total

1.  Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study.

Authors:  Marco Lamberti; Rosamaria Siracusano; Domenico Italiano; Norma Alosi; Francesca Cucinotta; Gabriella Di Rosa; Eva Germanò; Edoardo Spina; Antonella Gagliano
Journal:  Paediatr Drugs       Date:  2016-08       Impact factor: 3.022

2.  Using ADHD Medications to Treat Coexisting ADHD and Reading Disorders: A Systematic Review.

Authors:  Tanya E Froehlich; Jason Fogler; William J Barbaresi; Nada A Elsayed; Steven W Evans; Eugenia Chan
Journal:  Clin Pharmacol Ther       Date:  2018-08-30       Impact factor: 6.875

3.  Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial.

Authors:  Jeremy Veenstra-VanderWeele; Edwin H Cook; Bryan H King; Peter Zarevics; Maryann Cherubini; Karen Walton-Bowen; Mark F Bear; Paul P Wang; Randall L Carpenter
Journal:  Neuropsychopharmacology       Date:  2016-10-17       Impact factor: 7.853

4.  Guidance for identification and treatment of individuals with attention deficit/hyperactivity disorder and autism spectrum disorder based upon expert consensus.

Authors:  Susan Young; Jack Hollingdale; Michael Absoud; Patrick Bolton; Polly Branney; William Colley; Emily Craze; Mayuri Dave; Quinton Deeley; Emad Farrag; Gisli Gudjonsson; Peter Hill; Ho-Lan Liang; Clodagh Murphy; Peri Mackintosh; Marianna Murin; Fintan O'Regan; Dennis Ougrin; Patricia Rios; Nancy Stover; Eric Taylor; Emma Woodhouse
Journal:  BMC Med       Date:  2020-05-25       Impact factor: 8.775

Review 5.  Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology.

Authors:  Oliver D Howes; Maria Rogdaki; James L Findon; Robert H Wichers; Tony Charman; Bryan H King; Eva Loth; Gráinne M McAlonan; James T McCracken; Jeremy R Parr; Carol Povey; Paramala Santosh; Simon Wallace; Emily Simonoff; Declan G Murphy
Journal:  J Psychopharmacol       Date:  2017-12-14       Impact factor: 4.153

Review 6.  An update on medication management of behavioral disorders in autism.

Authors:  Danielle A Baribeau; Evdokia Anagnostou
Journal:  Curr Psychiatry Rep       Date:  2014-03       Impact factor: 5.285

7.  A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures.

Authors:  Laura C Politte; Lawrence Scahill; Janet Figueroa; James T McCracken; Bryan King; Christopher J McDougle
Journal:  Neuropsychopharmacology       Date:  2018-02-27       Impact factor: 7.853

Review 8.  ADHD in children and youth: Part 3-Assessment and treatment with comorbid ASD, ID, or prematurity.

Authors:  Brenda Clark; Stacey A Bélanger
Journal:  Paediatr Child Health       Date:  2018-10-24       Impact factor: 2.253

Review 9.  The Medical Care of People With Intellectual Disability.

Authors:  Tanja Sappok; Albert Diefenbacher; Martin Winterholler
Journal:  Dtsch Arztebl Int       Date:  2019-11-29       Impact factor: 5.594

10.  Stimulant Withdrawal in a Child with Autism Spectrum Disorder and ADHD - A Case Report.

Authors:  Aneta Krakowski; Abel Ickowicz
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2018-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.